Literature DB >> 10848792

Relapse after bone marrow transplantation: evidence for distinct immunological mechanisms between adult and paediatric populations.

M Guimond1, L Busque, C Baron, Y Bonny, R Bélanger, J Mattioli, C Perreault, D C Roy.   

Abstract

Donor lymphocyte infusions are particularly effective for remission induction in malignant cells in patients who relapse after allogeneic progenitor cell transplantation (PCT) and who remain sensitive to the administration of unprimed donor T and/or natural killer (NK) cells present in donor lymphocyte infusions. To determine whether relapse after unmanipulated PCT could be ascribed to donor T and/or NK cell loss or tolerization, we evaluated the chimeric status of 81 patients with haematological malignancies who were receiving allogeneic unmanipulated PCT. The incidence of mixed chimaerism (MC) in unfractionated mononuclear leucocyte samples decreased rapidly after transplant, and was not detectable 4 months after PCT, even in patients who subsequently relapsed. The chimeric status of immune effector cell subsets was then evaluated in 15 patients at the time of relapse. All adults demonstrated complete donor haematopoiesis (CDH) for all cell lineages, whereas T- and NK-cell MC was only found in patients younger than age 13 years (P = 0.004). MC was not found in T nor NK cells of a control group consisting of age-matched paediatric patients in remission after allogeneic PCT. Thus, in adults, T and NK cell MC disappears early after unmanipulated allogeneic PCT and is absent at the time of relapse. However, the identification of donor T and NK cell loss in the paediatric relapsed but not remission patients suggests a distinct mechanism of relapse.

Entities:  

Mesh:

Year:  2000        PMID: 10848792     DOI: 10.1046/j.1365-2141.2000.01961.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Second allogeneic peripheral blood stem cell transplantation with fludarabine-based low-intensity conditioning regimen for relapsed myelodysplastic syndrome after allogeneic bone marrow transplantation.

Authors:  N Kono; K Ohashi; E Sasaki; Y Okoshi; D Mizuchi; S Mori; H Akiyama; K Karasawa; H Kaku; R Okamoto; Y Maeda; T Sasaki; Y Okuyama; K Hiruma; H Sakamaki
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

2.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.

Authors:  Nicolaus Kröger; Ulrike Bacher; Peter Bader; Sebastian Böttcher; Michael J Borowitz; Peter Dreger; Issa Khouri; Homer A Macapinlac; Homer Macapintac; Eduardo Olavarria; Jerald Radich; Wendy Stock; Julie M Vose; Daniel Weisdorf; Andre Willasch; Sergio Giralt; Michael R Bishop; Alan S Wayne
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-14       Impact factor: 5.742

3.  Prediction of graft-versus-host disease in humans by donor gene-expression profiling.

Authors:  Chantal Baron; Roland Somogyi; Larry D Greller; Vincent Rineau; Peter Wilkinson; Carolyn R Cho; Mark J Cameron; David J Kelvin; Pierre Chagnon; Denis-Claude Roy; Lambert Busque; Rafick-Pierre Sékaly; Claude Perreault
Journal:  PLoS Med       Date:  2007-01       Impact factor: 11.069

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.